Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 1/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 16/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285228 | 0.88 | ROCK2 (0.68) | ROCK2PIM1GSK3BROCK1MAPT | |
| SCHEMBL4291905 | 0.88 | ROCK2 (0.68) | ROCK2PIM1GSK3BROCK1MAPT | |
| SCHEMBL4289384 | 0.86 | ROCK2 (0.63) | ROCK2PIM1GSK3BROCK1TP53 | |
| SCHEMBL3636663 | 0.85 | ROCK2 (0.59) | ROCK2PIM1GSK3BROCK1TP53 | |
| SCHEMBL4298374 | 0.84 | ROCK2 (0.62) | ROCK2PIM1GSK3BROCK1TP53 | |
| SCHEMBL4286440 | 0.83 | ROCK2 (0.67) | ROCK2PIM1GSK3BROCK1TP53 | |
| SCHEMBL4295851 | 0.83 | ROCK2 (0.67) | ROCK2PIM1GSK3BROCK1TP53 | |
| SCHEMBL4291700 | 0.83 | ROCK2 (0.63) | ROCK2PIM1GSK3BROCK1TP53 | |
| SCHEMBL3673482 | 0.82 | ROCK2 (0.66) | ROCK2PIM1GSK3BROCK1TP53 | |
| SCHEMBL3632707 | 0.82 | ROCK2 (0.66) | ROCK2PIM1GSK3BROCK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885PIM1 11/4885GSK3B 1/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | ROCK2 48/4885PIM1 11/4885GSK3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.